{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:57Z","timestamp":1793973597010,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Catholic Medical Center Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-86523-9","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T17:31:48Z","timestamp":1737999108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9818","authenticated-orcid":false,"given":"Se Jun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-0894","authenticated-orcid":false,"given":"Kabsoo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-2074","authenticated-orcid":false,"given":"In-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-0574","authenticated-orcid":false,"given":"MyungAh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-8104","authenticated-orcid":false,"given":"Tae Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-713X","authenticated-orcid":false,"given":"Hyunho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"86523_CR1","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1:EVIDoa2100070","journal-title":"NEJM Evid."},{"key":"86523_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382:1894\u20131905","journal-title":"N. Engl. J. Med."},{"key":"86523_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang, C. et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Reviews Gastroenterol. Hepatol. 20, 203\u2013222 (2023).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"86523_CR4","doi-asserted-by":"crossref","unstructured":"Rizzo, A. & Ricci, A. D. Vol. 23 11363 (MDPI, (2022).","DOI":"10.3390\/ijms231911363"},{"key":"86523_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/jpm12111788","volume":"12","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A., Ricci, A. D. & Brandi, G. Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update. J. Personalized Med. 12, 1788 (2022).","journal-title":"J. Personalized Med."},{"key":"86523_CR6","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC (2024) Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancer. 16:3689","journal-title":"Cancer."},{"key":"86523_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 17, 1455\u20131466 (2021).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"86523_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven, D. C. et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support. Care Cancer. 31, 624 (2023).","journal-title":"Support. Care Cancer"},{"key":"86523_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R. & Zhou, J. Targeted therapy for hepatocellular carcinoma. Signal. Transduct. Target. Therapy. 5, 146 (2020).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"86523_CR10","doi-asserted-by":"crossref","unstructured":"Vezhnovets, T., Gurianov, V., Prus, N., Korotkyi, O. & Antoniuk, O. Health care expenditures of 179 countries with different GNI per capita in 2018. (2021).","DOI":"10.36740\/WLek202103221"},{"key":"86523_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","volume":"8","author":"DW Kim","year":"2017","unstructured":"Kim, D. W., Talati, C. & Kim, R. Hepatocellular carcinoma (HCC): beyond sorafenib\u2014chemotherapy. J. Gastrointest. Oncol. 8, 256 (2017).","journal-title":"J. Gastrointest. Oncol."},{"key":"86523_CR12","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393, 1948\u20131957 (2019).","journal-title":"Lancet"},{"key":"86523_CR13","doi-asserted-by":"publisher","first-page":"HEP27","DOI":"10.2217\/hep-2020-0024","volume":"7","author":"A Aly","year":"2020","unstructured":"Aly, A., Ronnebaum, S., Patel, D., Doleh, Y. & Benavente, F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepatic Oncol. 7, HEP27 (2020).","journal-title":"Hepatic Oncol."},{"key":"86523_CR14","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su, D., Wu, B. & Shi, L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw. Open. 4, e210037\u2013e210037 (2021).","journal-title":"JAMA Netw. Open."},{"key":"86523_CR15","doi-asserted-by":"publisher","first-page":"e0300327","DOI":"10.1371\/journal.pone.0300327","volume":"19","author":"S Sriphoosanaphan","year":"2024","unstructured":"Sriphoosanaphan, S. et al. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand. Plos One. 19, e0300327 (2024).","journal-title":"Plos One"},{"key":"86523_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3748\/wjg.v20.i1.235","volume":"20","author":"JE Lee","year":"2014","unstructured":"Lee, J. E. et al. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J. Gastroenterology: WJG. 20, 235 (2014).","journal-title":"World J. Gastroenterology: WJG"},{"key":"86523_CR17","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.22.01142","volume":"41","author":"SH Li","year":"2023","unstructured":"Li, S. H. et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study. J. Clin. Oncol. 41, 1898 (2023).","journal-title":"J. Clin. Oncol."},{"key":"86523_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.17998\/jlc.2021.09.23","volume":"21","author":"BH Kim","year":"2021","unstructured":"Kim, B. H. & Park, J. W. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. J. Liver cancer. 21, 124 (2021).","journal-title":"J. Liver cancer"},{"key":"86523_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman, G. H., Abella, E. & Pettengell, R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit. Rev. Oncol. Hematol. 90, 190\u2013199 (2014).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"86523_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000339016","volume":"1","author":"DY Kim","year":"2012","unstructured":"Kim, D. Y. & Han, K. H. Epidemiology and surveillance of hepatocellular carcinoma. Liver cancer. 1, 2\u201314 (2012).","journal-title":"Liver cancer"},{"key":"86523_CR21","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.7314\/APJCP.2013.14.11.6227","volume":"14","author":"Y Yeo","year":"2013","unstructured":"Yeo, Y. et al. Viral hepatitis and liver cancer in Korea: an epidemiological perspective. Asian Pac. J. Cancer Prev. 14, 6227\u20136231 (2013).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"86523_CR22","doi-asserted-by":"crossref","unstructured":"Hong, S. Y., Kang, M. J., Kim, T., Jung, K. W. & Kim, B. W. Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999\u20132019. Annals of hepato-biliary-pancreatic surgery. 26, 211 (2022).","DOI":"10.14701\/ahbps.22-044"},{"key":"86523_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal, A. G., Lampertico, P. & Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J. Hepatol. 72, 250\u2013261 (2020).","journal-title":"J. Hepatol."},{"key":"86523_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14787210.2019.1573670","volume":"17","author":"M Schmidt-Hieber","year":"2019","unstructured":"Schmidt-Hieber, M., Teschner, D., Maschmeyer, G. & Schalk, E. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert Rev. anti-infective Therapy. 17, 983\u2013995 (2019).","journal-title":"Expert Rev. anti-infective Therapy"},{"key":"86523_CR25","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.aohep.2020.08.067","volume":"22","author":"M Mouchli","year":"2021","unstructured":"Mouchli, M., Reddy, S., Gerrard, M., Boardman, L. & Rubio, M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. Review article. Ann. Hepatol. 22, 100249 (2021).","journal-title":"Ann. Hepatol."},{"key":"86523_CR26","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364\u2013378 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"86523_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","volume":"43","author":"H Zhu","year":"2020","unstructured":"Zhu, H. et al. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell. Oncol. 43, 1203\u20131214 (2020).","journal-title":"Cell. Oncol."},{"key":"86523_CR28","doi-asserted-by":"crossref","unstructured":"Maruta, S. et al. Combination therapy of lenvatinib and hepatic arterial infusion chemotherapy using cisplatin with lipiodol and 5-fluorouracil: a potential breakthrough therapy for unresectable advanced hepatocellular carcinoma. Cureus 16, e66185 (2024).","DOI":"10.7759\/cureus.66185"},{"key":"86523_CR29","doi-asserted-by":"publisher","first-page":"1284937","DOI":"10.3389\/fimmu.2023.1284937","volume":"14","author":"Y Ding","year":"2023","unstructured":"Ding, Y. et al. The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma. Front. Immunol. 14, 1284937 (2023).","journal-title":"Front. Immunol."},{"key":"86523_CR30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"A Ally","year":"2017","unstructured":"Ally, A. et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341 (2017).","journal-title":"Cell"},{"key":"86523_CR31","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.2174\/1386207325666220304115006","volume":"25","author":"F Zhang","year":"2022","unstructured":"Zhang, F. et al. An immune-related gene signature predicting prognosis and immunotherapy response in hepatocellular carcinoma. Comb. Chem. High Throughput Screen. 25, 2203\u20132216 (2022).","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"86523_CR32","doi-asserted-by":"publisher","first-page":"879452","DOI":"10.3389\/fimmu.2022.879452","volume":"13","author":"WK Bae","year":"2022","unstructured":"Bae, W. K. et al. A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma. Front. Immunol. 13, 879452 (2022).","journal-title":"Front. Immunol."},{"key":"86523_CR33","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1245\/s10434-019-07580-9","volume":"26","author":"DI Tsilimigras","year":"2019","unstructured":"Tsilimigras, D. I. et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, a, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification. Ann. Surg. Oncol. 26, 3693\u20133700 (2019).","journal-title":"Ann. Surg. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86523-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86523-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86523-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T17:31:58Z","timestamp":1737999118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86523-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86523"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86523-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study conformed to Korean regulations and the Declaration of Helsinki. Ethical approval for data acquisition was obtained from the Institutional Review Board (IRB) of The Catholic University of Korea (approval ID: KC23RCDI0316). Informed consent was waived due to the retrospective nature of the study, as approved by the ethics committee of The Catholic University of Korea.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"STROBE statement"}}],"article-number":"3386"}}